ES2015348A6 - Procedimiento para purificar un inhibidor de interleuquina-1" - Google Patents

Procedimiento para purificar un inhibidor de interleuquina-1"

Info

Publication number
ES2015348A6
ES2015348A6 ES8802636A ES8802636A ES2015348A6 ES 2015348 A6 ES2015348 A6 ES 2015348A6 ES 8802636 A ES8802636 A ES 8802636A ES 8802636 A ES8802636 A ES 8802636A ES 2015348 A6 ES2015348 A6 ES 2015348A6
Authority
ES
Spain
Prior art keywords
materials
inhs
processes
biological materials
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES8802636A
Other languages
English (en)
Inventor
Jean Michel Dayer
Philippe Lucien Seckinger
Gonzalo Jose Mazzei
Alan Reed Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22218720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2015348(A6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of ES2015348A6 publication Critical patent/ES2015348A6/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)

Abstract

PROCEDIMIENTO PARA PURIFICAR UN INHIBIDOR DE INTERLEUQUINA-1. CONSISTE EN CONCENTRAR ORINA DE PACIENTES FEBRILES, PRECIPITAR UN INHIBIDOR DE INTERLEUQUINA-1 BRUTO A PARTIR DE LA ORINA CONCENTRADA Y FRACCIONAR DICHO INHIBIDOR MEDIANTE CROMATOGRAFIA DE INTERCAMBIO IONICO, CROMATOGRAFIA HIDROFOBA, FILTRACION EN GEL Y/O INMUNOABSORCION, EMPLEANDO PARA ELLO COLUMNAS DE QAE- O DEAE-SEPHAROSE, COLUMNAS DE FENIL-SEPHAROSE, COLUMNAS DE ULTRAFILTRACION EN ULTROGEL ACA Y/O ANTICUERPOS MONOCLONALES O POLICLONALES PARA PROTEINA DE FIJACION DE RETINOL Y PARA APOLIPOPROTEINA. LOS PRODUCTOS OBTENIDOS SON UTILES PARA INHIBIR LAS ACTIVIDADES LAF Y MCF DE INTERLEUQUINA-1 Y LA PROLIFERACION DE FIBROBLASTOS, SIN AFECTAR A LA PRODUCCION DE PGESI2 Y COLAGENASA, Y PUEDEN APLICARSE A TERAPIAS INMUNOSUPRESORAS Y ANTIINFLAMATORIAS.
ES8802636A 1987-08-26 1988-08-25 Procedimiento para purificar un inhibidor de interleuquina-1" Expired - Fee Related ES2015348A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8963287A 1987-08-26 1987-08-26

Publications (1)

Publication Number Publication Date
ES2015348A6 true ES2015348A6 (es) 1990-08-16

Family

ID=22218720

Family Applications (3)

Application Number Title Priority Date Filing Date
ES8802636A Expired - Fee Related ES2015348A6 (es) 1987-08-26 1988-08-25 Procedimiento para purificar un inhibidor de interleuquina-1"
ES8903150A Expired - Fee Related ES2017275A6 (es) 1987-08-26 1989-09-16 Un procedimiento para producir un inhibidor de interleuquina-1(inh de il-1) sustancialmente puro>
ES8903149A Expired - Fee Related ES2017274A6 (es) 1987-08-26 1989-09-16 Un metodo de producir una molecula de adn recombinante.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES8903150A Expired - Fee Related ES2017275A6 (es) 1987-08-26 1989-09-16 Un procedimiento para producir un inhibidor de interleuquina-1(inh de il-1) sustancialmente puro>
ES8903149A Expired - Fee Related ES2017274A6 (es) 1987-08-26 1989-09-16 Un metodo de producir una molecula de adn recombinante.

Country Status (20)

Country Link
EP (1) EP0341273B1 (es)
JP (2) JP3014099B2 (es)
KR (2) KR0138919B1 (es)
AT (1) ATE147408T1 (es)
AU (1) AU633471B2 (es)
BE (1) BE1002375A3 (es)
CA (1) CA1341026C (es)
DE (1) DE3855747T2 (es)
DK (1) DK175837B1 (es)
ES (3) ES2015348A6 (es)
FR (1) FR2621821A1 (es)
GB (1) GB2220662A (es)
HK (1) HK1007748A1 (es)
IL (1) IL87543A0 (es)
IT (1) IT1226855B (es)
NL (1) NL8820676A (es)
NZ (1) NZ225940A (es)
SE (1) SE8901342D0 (es)
WO (1) WO1989001946A1 (es)
ZA (1) ZA886251B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
KR0148009B1 (ko) * 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
JP3192651B2 (ja) * 1988-05-27 2001-07-30 アムジェン，インコーポレーテッド インターロイキン―１インヒビター
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
AU651955B2 (en) * 1989-11-29 1994-08-11 Amgen, Inc. Production of recombinant human interleukin-1 inhibitor
US5714140A (en) * 1989-12-13 1998-02-03 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting the production of bioactive IL-1 by administering M-CSF
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
WO1991017184A1 (en) * 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
WO1991017249A1 (en) * 1990-05-01 1991-11-14 Cetus Corporation Interleukin-1 antagonist and uses thereof
WO1997009984A1 (en) * 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Immunosuppressant
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992367A (en) * 1986-05-12 1991-02-12 Hoffmann-La Roche Inc. Enhanced expression of human interleukin-2 in mammalian cells

Also Published As

Publication number Publication date
IT8821743A0 (it) 1988-08-25
DE3855747D1 (de) 1997-02-20
NL8820676A (nl) 1989-07-03
IL87543A0 (en) 1989-01-31
NZ225940A (en) 1992-06-25
EP0341273B1 (en) 1997-01-08
JP3217752B2 (ja) 2001-10-15
KR0138919B1 (ko) 1998-04-30
FR2621821A1 (fr) 1989-04-21
DK203189A (da) 1989-04-26
JPH10327862A (ja) 1998-12-15
SE8901342L (sv) 1989-04-13
ATE147408T1 (de) 1997-01-15
JP3014099B2 (ja) 2000-02-28
AU2427288A (en) 1989-03-31
ZA886251B (en) 1990-04-25
KR890701629A (ko) 1989-12-21
JPH02500643A (ja) 1990-03-08
HK1007748A1 (en) 1999-04-23
ES2017275A6 (es) 1991-01-16
KR0138654B1 (ko) 1998-04-30
EP0341273A4 (en) 1990-09-19
DK203189D0 (da) 1989-04-26
DK175837B1 (da) 2005-03-21
IT1226855B (it) 1991-02-19
DE3855747T2 (de) 1997-06-12
WO1989001946A1 (en) 1989-03-09
BE1002375A3 (fr) 1991-01-22
GB2220662A (en) 1990-01-17
GB8912533D0 (en) 1989-08-02
EP0341273A1 (en) 1989-11-15
AU633471B2 (en) 1993-02-04
CA1341026C (en) 2000-06-13
ES2017274A6 (es) 1991-01-16
SE8901342D0 (sv) 1989-04-13

Similar Documents

Publication Publication Date Title
ATE113295T1 (de) Tumornekrosefaktor, verfahren zu seiner herstellung, denselben enthaltende zusammensetzungen, dafür kodierende dns und diese dns verwendendes testverfahren.
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
GB9323165D0 (en) Compounds
ES2017275A6 (es) Un procedimiento para producir un inhibidor de interleuquina-1(inh de il-1) sustancialmente puro>
DK0398327T4 (da) Tumornekrosefaktor-bindende protein, dets oprensning og antistoffer dertil
ATE314116T1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
NZ257484A (en) Nucleotides active against tnf-alpha, treatment of viral diseases
Naldini et al. Inhibition of interleukin‐12 expression by α‐thrombin in human peripheral blood mononuclear cells: a potential mechanism for modulating Th1/Th2 responses
ES2117717T3 (es) Tratamiento de tumores con factores neurotroficos e inhibidores de la proliferacion celular.
Kolke et al. The Production of Heparin Cofactor li Is Not Regulated by Inflammatory Cytokines in Human Hepatoma Cells: Comparison with Plasminogen Activator Inhibitor Type-1
DE69222636D1 (de) Anti-hiv protein, tap-29, aus trichosanthes, seine kodierende dna und therapeutischen anwendungen

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20080826